JPS6475431A - Novel protease preparation - Google Patents
Novel protease preparationInfo
- Publication number
- JPS6475431A JPS6475431A JP63210670A JP21067088A JPS6475431A JP S6475431 A JPS6475431 A JP S6475431A JP 63210670 A JP63210670 A JP 63210670A JP 21067088 A JP21067088 A JP 21067088A JP S6475431 A JPS6475431 A JP S6475431A
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- protease preparation
- thrombosis
- remedy
- substrate specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091005804 Peptidases Proteins 0.000 title abstract 3
- 239000004365 Protease Substances 0.000 title abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 3
- 241000361919 Metaphire sieboldi Species 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 230000020764 fibrinolysis Effects 0.000 abstract 2
- 229940012957 plasmin Drugs 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 108010039627 Aprotinin Proteins 0.000 abstract 1
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 abstract 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 229960004405 aprotinin Drugs 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000010102 embolization Effects 0.000 abstract 1
- 230000001471 fibrinogenolytic effect Effects 0.000 abstract 1
- 230000003480 fibrinolytic effect Effects 0.000 abstract 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
- 229960005356 urokinase Drugs 0.000 abstract 1
- 210000004127 vitreous body Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
PURPOSE:To obtain a protease preparation which is used as a remedy for thrombosis from a fraction of earthworm extract, thus having fibrinolytic action, but not fibrinogenolytic action, and substrate specificity and high heat stability. CONSTITUTION:The subject protease preparation is extracted for earthworm and has physiological actions to cause fibrinolysis, but not fibrinogenolysis, activate plasminogen to form plasmin, substrate specificity to act on a synthetic medium of urokinase and plasmin and thermal stability. The pharmaceutical preparation is used for prophylactic or remedy for thrombosis and vitreous body bleeding, as an anticoagulant in blood transfusion and for prevention of the embolization along the seam lines in blood vessels, as it shows excellent fibrinolysis and thrombolysis. The preparation is inhibited by aprotinin but not by trans-4-aminomethylcyclohexanecarboxylic acid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR870010309A KR890004724A (en) | 1987-09-17 | 1987-09-17 | New protease preparations |
| KR1987-10309 | 1987-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6475431A true JPS6475431A (en) | 1989-03-22 |
| JP2716472B2 JP2716472B2 (en) | 1998-02-18 |
Family
ID=19264546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63210670A Expired - Fee Related JP2716472B2 (en) | 1987-09-17 | 1988-08-26 | New protease preparation |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2716472B2 (en) |
| KR (1) | KR890004724A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006101140A1 (en) * | 2005-03-22 | 2006-09-28 | Sodx Co., Ltd. | Novel protease, microorganism producing the same, and application thereof |
| CN100406470C (en) * | 2001-03-30 | 2008-07-30 | 科学和工业研究委员会 | A protein that causes sperm immobility from the coelomial fluid of an Indian earthworm |
| JP2008201801A (en) * | 1999-02-22 | 2008-09-04 | Baxter Internatl Inc | Novel factor VIII formulation not containing albumin |
| CN103263660A (en) * | 2013-05-13 | 2013-08-28 | 肖梅芬 | Earthworm protein for reducing blood sugar and blood pressure and eliminating diabetic complications and application pf earthworm protein |
| US8560404B2 (en) | 2000-03-08 | 2013-10-15 | Sony Corporation | Information service methods for facilitating browsing and purchasing of consumer commodities in a broadcast program |
| CN103845273A (en) * | 2014-03-14 | 2014-06-11 | 江苏隆力奇生物科技股份有限公司 | Lumbricus peptide capable of resisting skin aging as well as preparation method and application thereof |
| JP2016086736A (en) * | 2014-11-05 | 2016-05-23 | 日立化成株式会社 | Production method of liquid containing rare cells in blood |
| US10512674B2 (en) | 2008-11-07 | 2019-12-24 | Baxalta Incorporated | Factor VIII formulations |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2105139T3 (en) | 2008-03-26 | 2010-10-25 | Well Stone Co | Process for preparing a dry earthworm powder |
| CN101584853B (en) * | 2009-06-15 | 2012-12-19 | 南京中医药大学 | Earthworm protein polypeptide preparation |
| CN103239706B (en) * | 2013-05-13 | 2014-11-26 | 肖梅芬 | Earthworm protein for reducing blood glucose, improving microcirculation and eliminating diabetic complication and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5963184A (en) * | 1982-10-02 | 1984-04-10 | Amano Pharmaceut Co Ltd | Novel protease |
| JPS59184131A (en) * | 1983-03-31 | 1984-10-19 | Amano Pharmaceut Co Ltd | Thrombolytic agent |
-
1987
- 1987-09-17 KR KR870010309A patent/KR890004724A/en not_active Ceased
-
1988
- 1988-08-26 JP JP63210670A patent/JP2716472B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5963184A (en) * | 1982-10-02 | 1984-04-10 | Amano Pharmaceut Co Ltd | Novel protease |
| JPS59184131A (en) * | 1983-03-31 | 1984-10-19 | Amano Pharmaceut Co Ltd | Thrombolytic agent |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014024864A (en) * | 1999-02-22 | 2014-02-06 | Baxter Internatl Inc | Novel albumin-free factor viii formulation |
| US9669076B2 (en) | 1999-02-22 | 2017-06-06 | Baxalta Incorporated | Albumin-free factor VIII formulations |
| JP2008201801A (en) * | 1999-02-22 | 2008-09-04 | Baxter Internatl Inc | Novel factor VIII formulation not containing albumin |
| JP2009046499A (en) * | 1999-02-22 | 2009-03-05 | Baxter Internatl Inc | Novel factor VIII formulation not containing albumin |
| JP2012072198A (en) * | 1999-02-22 | 2012-04-12 | Baxter Internatl Inc | Novel albumin-free factor viii formulation |
| US9352027B2 (en) | 1999-02-22 | 2016-05-31 | Baxalta Incorporated | Albumin-free factor VIII formulations |
| US8560404B2 (en) | 2000-03-08 | 2013-10-15 | Sony Corporation | Information service methods for facilitating browsing and purchasing of consumer commodities in a broadcast program |
| CN100406470C (en) * | 2001-03-30 | 2008-07-30 | 科学和工业研究委员会 | A protein that causes sperm immobility from the coelomial fluid of an Indian earthworm |
| WO2006101140A1 (en) * | 2005-03-22 | 2006-09-28 | Sodx Co., Ltd. | Novel protease, microorganism producing the same, and application thereof |
| US10512674B2 (en) | 2008-11-07 | 2019-12-24 | Baxalta Incorporated | Factor VIII formulations |
| US11020459B2 (en) | 2008-11-07 | 2021-06-01 | Baxalta Incorporated | Factor VIII formulations |
| CN103263660A (en) * | 2013-05-13 | 2013-08-28 | 肖梅芬 | Earthworm protein for reducing blood sugar and blood pressure and eliminating diabetic complications and application pf earthworm protein |
| CN103845273A (en) * | 2014-03-14 | 2014-06-11 | 江苏隆力奇生物科技股份有限公司 | Lumbricus peptide capable of resisting skin aging as well as preparation method and application thereof |
| JP2016086736A (en) * | 2014-11-05 | 2016-05-23 | 日立化成株式会社 | Production method of liquid containing rare cells in blood |
Also Published As
| Publication number | Publication date |
|---|---|
| KR890004724A (en) | 1989-05-09 |
| JP2716472B2 (en) | 1998-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4988115B2 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| Collen et al. | Basic and clinical aspects of fibrinolysis and thrombolysis | |
| HUT58812A (en) | Process for producing tissue plasminogen activator (t-pa) zimogenes and compositions containing them as active components | |
| US4935237A (en) | Processes for the preparation of t-PA mutants | |
| Markland | Rattlesnake venom enzymes that interact with components of the hemostatic system | |
| EP0273774A3 (en) | Plasminogen activators, dna encoding the same and their preparation and use | |
| US5747291A (en) | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect | |
| BANG | Physiology and biochemistry of fibrinolysis | |
| KR890004724A (en) | New protease preparations | |
| DK175369B1 (en) | Use of tPA variants for the preparation of a therapeutic composition for the treatment of vascular disorders | |
| EP0324597A2 (en) | Fibrin selective two-chain plasminogen activator | |
| Samama et al. | Urokinase I and II activity | |
| Bachmann | Fibrinolytic agents | |
| EP0338409B1 (en) | Low molecular weight derivatives of prourokinase and pharmaceutical compositions containing the same | |
| Gilboa et al. | Inhibition of fibrinolytic enzymes by thrombin inhibitors | |
| ZA887556B (en) | Modified tissue plasminogen activator | |
| Nakayama et al. | The plasmin heavy chain-urokinase conjugate: a specific thrombolytic agent | |
| Lijnen et al. | Molecular mechanisms of thrombolytic therapy | |
| DK0517756T3 (en) | Tissue plasminogen activator with fibrin-specific properties | |
| Guerrero et al. | Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model | |
| EP0487660B1 (en) | Treatment of thrombotic events | |
| KR100419451B1 (en) | Protein with thrombolytic activities extracted from natural product | |
| KR101106507B1 (en) | Thrombolytic enzyme derived from longevity mushroom mycelium | |
| Wong et al. | Demonstration of the presence of plasminogen activator in human small intestine | |
| Rickli | Plasminogen and Plasmin as Key-Substances within the Fibrinolytic System |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |